Abstract | BACKGROUND: METHOD: We analyzed the subjective symptoms (spontaneous pain, numbness, coldness and hypoesthesia) and the nerve function tests (motor nerve conduction velocity, sensory nerve conduction velocity and vibration threshold). RESULT: The improvement rate of the subjective symptoms was 75% (slightly improved or better) and that of the nerve function tests 36%. Adverse drug reactions were encountered in 52 (2.5%) of the 2190 patients, none of which was severe. CONCLUSION: Although data are limited, it is strongly suggested that epalrestat is a highly effective and safe agent for the treatment of diabetic neuropathy.
|
Authors | S R Sharma, Nalini Sharma |
Journal | Annals of Indian Academy of Neurology
(Ann Indian Acad Neurol)
Vol. 11
Issue 4
Pg. 231-5
(Oct 2008)
ISSN: 1998-3549 [Electronic] India |
PMID | 19893679
(Publication Type: Journal Article)
|